ABOUT US
Welcome to EpiEndo Pharmaceuticals
EpiEndo is a clinical stage pharmaceutical company developing a proprietary portfolio of drugs to address the huge global burden of chronic respiratory diseases. Over more than a decade our research into the disease etiology of chronic obstructive pulmonary disease (COPD) has led to our unique insights in inflammatory processes.
Our new class of orally-available macrolide candidate NCEs show promise as first-in-class disease-modifying therapeutics for COPD. Our lead compound is a non-antibiotic analogue of azithromycin which modulates inflammation through strengthening the lung epithelium. We are actively exploring additional potential applications for post COVID-19 treatment, where the established anti-inflammatory properties of our technology may be of value.
OUR TEAM
We operate an agile business with an experienced core team based across Iceland, Sweden, Germany and the UK, supported by global key opinion leaders and pulmonary specialists, with contractors and consultants filling other key functions.
Executive Leadership
Stefán Pétursson,Cand Oecon.
CFO
Jennifer Kricker, PhD
Head of Research
Ginny Norris, MD
CMO
Board
Hilmar Bragi Janusson, PhD
Chairman of the Board
Carl Johan Spak, PhD
Board Member
Prof Clive Page, OBE, PhD
Board Member
Dr. Eugen Steiner
Board Member
Ívar Guðjónsson, MBA
Board Member
Isaac Cohen, PhD
Board Member
Senior Advisors
Prof Þórarinn Guðjónsson
SAB
Ólafur Baldursson, MD
SAB
Prof Dave Singh, MD
SAB